Study | Health state | Utility valuea | Instrument | Tariff | Respondent details | HTA suitability |
---|---|---|---|---|---|---|
1st line | ||||||
Nafees 2016 [68] Metastatic NSCLCb | PD vs BL state | 0.095 | TTO | N/A | Patients (but not NSCLC patients) from the general public in UK, Australia, France, China, S. Korea, Taiwan | No |
RES no side effects vs BL | 0.773 | |||||
SDis no side effects vs BL | 0.460 | |||||
Chevalier 2013c [38] Advanced/metastatic NSCLC | 1 L PF | 0.69 (0.26) | EQ-5D | French (TTO) | Stage I–Stage III/IV PF and PD | Meets HAS requirements |
1 L PD | 0.61 (0.24) | |||||
Chouaid 2013 [39] Advanced/metastatic NSCLC | 1 L PF | 0.71 (0.24) (95% CI, 0.67–0.76) | EQ-5D-3 L | UK | At time of advanced diagnosis, mean age 64.8 years Adenocarcinoma: 65.2% Large-cell carcinoma: 6.8% SQ cell carcinoma: 17.1% Other: 9.9% Clinical stage at time of survey: IIIb: 17.9% IV: 82.1% | Meets NICE requirements |
69.31 (18.33) (95% CI, 65.9–72.8) | EQ-5D VAS | N/A | No | |||
1 L PD | 0.67 (0.2) (95% CI 0.59–0.75) | EQ-5D-3 L | UK | Meets NICE requirements | ||
58.67 (17.4) (95% CI 51.3–66.0) | EQ-5D VAS | N/A | No | |||
Iyer 2013 [46] Advanced/metastatic NSCLC | France, Germany 1 L | 0.63 (0.31) | EQ-5D | UK1 | Patients with: Adenocarcinoma: 56.3% Large-cell carcinoma: 11.8% SQ cell carcinoma: 29.3% Other: 2.5% Stage IIIb: 15.4% Stage: IV 84.6% | Meets NICE requirement |
60.8 (19.9) | EQ-5D VAS | N/A | No | |||
≥ 1st line | ||||||
Iyer 2013 [46] Advanced/metastatic NSCLC | France, Germany 1 L/2 L | 0.58 (0.35) | EQ-5D | UK | Patients with: Adenocarcinoma: 56.3% Large-cell carcinoma: 11.8% SQ cell carcinoma: 29.3% Other: 2.5% Stage IIIb: 15.4% Stage: IV 84.6% | Meets NICE and SMC requirements |
France, 1 L/2 L | 0.57 (0.41) | |||||
Germany, 1 L/2 L | 0.59 (0.31) | |||||
France, Germany 1 L/2 L | 58.0 (19.9) | EQ-5D VAS | No | |||
France, 1 L/2 L | 57.1 (21.1) | |||||
Germany, 1 L/2 L | 58.6 (19.1) | |||||
2nd line | ||||||
Blackhall 2014 [41] Advanced/metastatic ALK+ NSCLC | 2 L BL CRZ | 0.73 (0.24) | EQ-5D-3 L | NR | Multinational patients, locally advanced/metastatic ALK+ NSCLC, 2 L | Unclear as tariff NR |
2 L BL chemotherapy (PEM or DOC) | 0.70 (0.26) | |||||
2 L BL PEM | 0.73 (0.24) | |||||
2 L BL DOC | 0.67 (0.29) | |||||
2 L on CRZ | 0.82 (SE, 0.01) (95% CI, 0.79–0.85) | |||||
2 L on Chemotherapy | 0.73 (SE, 0.02) (95% CI, 0.70–0.77) | |||||
2 L on PEM | 0.74 (SE, 0.02) (95% CI, 0.70–0.79) | |||||
2 L on DOC | 0.66 (SE, 0.04) (95% CI, 0.58–0.74) | |||||
Chevalier 2013c [38] Advanced/metastatic NSCLC | 2 L PF | 0.70 (0.22) | EQ-5D | French (TTO) | Stage I–Stage III/IV PF and PD | Meets HAS requirements |
2 L PD | 0.55 (0.35) | |||||
Chouaid 2013 [39] Advanced/metastatic NSCLC | 2 L PF | 0.74 (0.18) (95% CI, 0.68–0.80) | EQ-5D-3 L | UK | At time of advanced diagnosis, mean age 64.8 years Adenocarcinoma: 65.2% Large-cell carcinoma: 6.8% SQ cell carcinoma: 17.1% Other: 9.9% Clinical stage at time of survey: IIIb: 17.9% IV: 82.1% | Meets NICE requirements |
65.0 (19.6) (95% CI, 59.2–70.8) | EQ-5D VAS | N/A | No | |||
2 L PD | 0.59 (0.34) (95% CI, 0.42–0.77) | EQ-5D-3 L | UK | Meets NICE requirements | ||
53.5 (23.3) (95% CI, 41.5–65.4) | EQ-5D VAS | N/A | No | |||
Huang 2016c [45] Advanced PD-L1+ NSCLC | 2 L PF | 0.76 (95% CI, 0.75–0.77) | EQ-5D | NR | Multinational patients with advanced NSCLC and PD-L1+ tumours in 2 L on PEMB or DOC, after platinum-based chemotherapy | Unclear as tariff NR |
2 L PD | 0.69 (95% CI, 0.66–0.71) | |||||
Advanced PD-L1+ NSCLC, 2 L, > 360 days from death | 0.81 (0.79, 0.83) | Patients with advanced NSCLC and PD-L1+ tumours in 2 L on PEMB or DOC, after platinum-based chemotherapy | ||||
Advanced PD-L1+ NSCLC, 2 L, 180–360 days from death | 0.73 (0.71, 0.75) | |||||
Advanced PD-L1+ NSCLC, 2 L, 90–180 days from death | 0.69 (0.66, 0.72) | |||||
Advanced PD-L1+ NSCLC, 2 L, 30–90 days from death | 0.60 (0.56, 0.64) | |||||
Advanced PD-L1+ NSCLC, 2 L, < 30 days from death | 0.40 (0.31, 0.48) | |||||
Iyer 2013 [46] Advanced/metastatic NSCLC | On treatment: 2 L only | 0.53 (0.38) | EQ-5D | UK | French and German patients | Meets NICE and SMC requirements |
54.9 (19.3) | EQ-5D VAS | N/A | No | |||
Langley 2013 [48] Stage IV NSCLC with brain metastases | NSCLC with BM, previous tx allowed, OSC + WBRT 0 days | 0.63 | EQ-5D | NRd | UK and Australian NSCLC patients with brain metastases | No, as VAS tariff used |
NSCLC with BM, previous tx allowed, OSC + WBRT 28 days | 0.49 | |||||
NSCLC with BM, previous tx allowed, OSC + WBRT 56 days | 0.39 | |||||
NSCLC with BM, previous tx allowed, OSC + WBRT 112 days | 0.36 | |||||
NSCLC with BM, previous tx allowed, OSC + WBRT 168 days | 0.16 | |||||
NSCLC with BM, previous tx allowed, OSC alone 0 days | 0.60 | |||||
NSCLC with BM, previous tx allowed, OSC alone 28 days | 0.49 | |||||
NSCLC with BM, previous tx allowed, OSC alone 56 days | 0.44 | |||||
NSCLC with BM, previous tx allowed, OSC alone 112 days | 0.38 | |||||
NSCLC with BM, previous tx allowed, OSC alone 168 days | 0.36 | |||||
Lloyd 2008 [59] Cancer with chemotherapy-related anaemia or fatigue | Anaemia, Hb level, ≥12.0 g/dL | 0.708 (95% CI, 0.057) | SG | N/A | General public sample from UK | No |
0.611 (95% CI, 0.112) | TTO | UK cancer patients who have recently experienced chemotherapy-related fatigue and anaemia completing vignette-based TTO | Meets NICE/SMC requirements but still vignette-based health state rather than patient rating own health | |||
Nafees 2008 [59] mNSCLC | 2 L Stable diseasee | 0.65 (SE, 0.02) | SG | N/A | 100 members of general public in UK | No, but used in multiple HTA submissions |
2 L Responding diseasef | 0.67 | |||||
2 L Response gain | 0.02 (SE, 0.01) | |||||
2 L Progressive diseaseg | 0.47 | |||||
Novello 2015 [49] Stage III/IV recurrent NSCLC (SQ and NSQ)h | 2 L NIN + DOC, before treatment (week 0) | 0.72 | EQ-5D | UK | Multinational patients with stage III/IV recurrent NSCLC (SQ and NSQ) in 2 L after chemotherapy Adenocarcinoma: 50.1% | Meets NICE/SMC requirements |
2 L NIN + DOC, after treatment (week 30) | 0.61 | |||||
2 L PLA + DOC, before treatment (week 0) | 0.72 | |||||
2 L PLA + DOC, after treatment (week 30) | 0.62 | |||||
2 L NIN + DOC, before treatment (week 0) | 69.0 | EQ-5D VAS | N/A | No | ||
2 L NIN + DOC, after treatment (week 30) | 63.2 | |||||
2 L PLA + DOC, before treatment (week 0) | 69.0 | |||||
2 L PLA + DOC, after treatment (week 30) | 63.1 | |||||
Reck 2015 [50] Advanced SQ NSCLC | 2 L NIVO at BL | 0.68 (0.208) | EQ-5D | NR | Multinational patients with advanced SQ NSCLC | Unclear as tariff NR |
2 L DOC at BL | 0.66 (0.284) | |||||
2 L NIVO at BL | 63.7 (18.2) | EQ-5D VAS | N/A | No | ||
2 L DOC at BL | 66.3 (20.5) | |||||
Rudell 2016c [57] Advanced NSCLC, EGFR+ | 2 L OSI at BL | 65.2 (20.33) | EQ-5D-5 L VAS | N/A | Multinational patients with EGFR+ advanced NSCLC, 2 L after previous TKI | No |
2 L OSI at 36 weeks | 73.7 (17.33) | |||||
Schuette 2012 [51] NSCLC Stage IIIB–IV | 2 L, PEM at BL | 0.66 (0.256) | EQ-5D | UK TTO | Austrian and German advanced/mNSCLC 2 L patients mainly after prior platinum treatment (IIIa, 6.7%; IIIb, 19.8%; IV, 73.5%) | Meets NICE/SMC requirements |
2 L, PEM at 6 weeks (2nd cycle) | 0.02 (0.214) | EQ-5D gain | ||||
2 L, PEM at 6th cycle | 0.11 (0.228) | |||||
2 L, PEM at BL | 59.3 (17.8) | EQ-5D VAS | N/A | No | ||
2 L, PEM at 6 weeks (2nd cycle) | 3.3 (12.58) | EQ-5D VAS gain | N/A | |||
2 L, PEM at 6th cycle | 12.8 (17.62) | |||||
Vargas 2009c [72] Advanced NSCLC | 2 L, on ERL | 0.81 | Global QoL index | NR | Patients with advanced NSCLC, 2 L after previous chemotherapy | No |
2 L, on taxanes | 0.62 | |||||
≥ 2nd line | ||||||
Chen 2010c [73] Advanced NSCLCd | 2 L, DOC, during treatment | 0.45i | SG | N/A | UK general public (as algorithm based on Nafees 2008 data used to calculate utilities) | Acceptable data for SMC |
2 L, DOC, after treatment | 0.57 | |||||
2 L, PEM, during treatment | 0.54 | |||||
2 L, PEM, after treatment | 0.59 | |||||
3 L, ERL, during treatment | 0.48 | |||||
BSC, during treatment | 0.47 | |||||
Chevalier 2013 [38] Advanced/metastatic NSCLC | 3/4 L PF | 0.61 (0.3) | EQ-5D | French (TTO) | Stage I–Stage III/IV PF and PD | Meets HAS requirements |
3/4 L PD | 0.42 (0.40) | |||||
Griebsch 2014 [37] Stage IIIb (with pleural effusion)/IV NSCLC adenocarcinoma (LUX-LUNG 1)j | Week 4, progression effect longitudinal model | −0.1 | EQ-5D | UK | Multinational advanced/metastatic NSCLC, 2 LL | Meets NICE requirements |
Mixed effect longitudinal model IRC | −0.056 (95% CI, − 0.083 to − 0.028) | |||||
Mixed effect longitudinal model IN | −0.065 (95% CI, − 0.092 to − 0.039) | |||||
Mixed effect longitudinal model IRC, AFA | −0.06 | |||||
Mixed effect longitudinal model IRC, BSC | −0.046 | |||||
Mixed effect longitudinal model IINV, AFA | −0.081 | |||||
Mixed effect longitudinal model IINV, BSC | −0.033 | |||||
Week 4, progression effect longitudinal model | −7.3 | EQ-5D VAS | N/A | No | ||
Mixed effect longitudinal model IRC | −3.76 (95% CI, −5.19 to −2.32) | |||||
Mixed effect longitudinal model INV | − 3.83 (95% CI, − 5.21 to − 2.44) | |||||
Mixed effect longitudinal model IRC, AFA | 3.63 | |||||
Mixed effect longitudinal model IRC, BSC | −4.11 | |||||
Mixed effect longitudinal model INV, AFA | −4.42 | |||||
Mixed effect longitudinal model INV, BSC | −2.55 | |||||
Hirsh 2013 [40] Stage IIIB/IV NSCLC | 3 LL on AFA + BSC | 0.71 | EQ-5D | UK | 98% adenocarcinoma PD following treatment lines 1–2, one of which was platinum based, plus PD after at least 12 weeks of ERL or GEF | Meets NICE requirements |
3 LL on PLA + BSC | 0.67 | |||||
3 LL on AFA + BSC | 67.4 | EQ-5D VAS | N/A | No | ||
3 LL on PLA + BSC | 65.2 | |||||
Schwartzbergc 2015 [60] Stage IIIb/IV NSCLC (SQ & NSQ) | All patients wk 6 | 1.0 (21.7) | EQ-5D VAS | N/A | Patients, 2 LL, NIVO 3 mg/kg i.v. q2w | No |
wk 12 | 5.8 (21.3) | |||||
wk 18 | 8.2 (22.3) | |||||
wk 24 | 8.2 (23.9) | |||||
wk 30 | 8.4 (29.2) | |||||
SDis wk 6 | 3.8 (19.8) | |||||
wk 12 | 6.4 (21.9) | |||||
wk 18 | 8.2 (20.9) | |||||
wk 24 | 5.2(21.9) | |||||
wk 30 | 7.2 (28.5) | |||||
PR wk 6 | 7.3 (22.4) | |||||
wk 12 | 6.6 (24.7) | |||||
wk 18 | 8.1 (27.6) | |||||
wk 24 | 18.1 (31.0) | |||||
wk 30 | 13.7 (38.2) | |||||
PD wk 6 | −5.8 (21.1) | |||||
wk 12 | −3.0 (19.8) | |||||
wk 18 | 3.9 (24.3) | |||||
wk 24 | 6.8 (12.2) | |||||
wk 30 | 5.5 (15.7) | |||||
Treatment line not specified | ||||||
Bradbury 2008c [42] Advanced NSCLC | On ERL | 0.772 | EQ-5D | NR (possibly Canadian) | Canadian patients | Potentially relevant to CADTH |
On BSC | 0.754 | |||||
Chang 2016c [63] Advanced NSCLC | > 360 days from death | 0.904 (95% CI, 0.892–0.917) | TTO | NR | General public, South Korea | No |
180–360 days from death | 0.720 (95% CI, 0.692–0.748) | |||||
90–180 days from death | 0.627 (95% CI, 0.598–0.655) | |||||
30–90 days from death | 0.379 (95% CI, 0.349–0.409) | |||||
< 30 days from death | 0.195 (95% CI, 0.172–0.218) | |||||
Dansk 2016c [43] Advanced NSCLC | Synthesized PF | Median, 0.706 Range, 0.620–0.815 | Synthesized utility across > 1 instrument type | NR | Utilities synthesized included those where respondents were patients and those where they were the general public considering a hypothetical health state | No |
Synthesized PF trial-based | Median, 0.750 Range, 0.627–0.815 | |||||
Synthesized PF non-trial-based | Median, 0.653 Range, 0.620–0.653 | |||||
Synthesized PD | Median, 0.565 Range, 0.470–0.688 | |||||
Synthesized PD trial-based | Median, 0.599 Range, 0.550–0.688 | |||||
Synthesized PD non-trial-based | Median, 0.473 Range, 0.470–0.530 | |||||
Doyle 2008 [65] Metastatic NSCLC | SDis, no additional symptoms | 0.626 | SG | N/A | General public | No |
Treatment response, no additional symptoms | 0.712 | |||||
Grunberg 2009c [58] BC/LC | Chemotherapy-induced nausea and vomiting of differing severity | Reported graphically | SG | N/A | Patients BC/LC | Meets NICE requirements |
Grutters 2010c [44] NSCLC (stage unspecified) | NSCLC with grade 3+ dyspnoea, stage unspecified | Median, 0.52 | EQ-5D-5 L | NR | Patients at an early treatment stage | No |
Jang 2010 [47] Stage IV NSCLC | Stage IV NSCLC | 0.75 (0.15) | EQ-5D | US | Patients with NSCLC attending a major Canadian cancer center outpatient clinic | No |
Linnet 2015c [62] Stage IV NSCLC on oral VINO | PCS, cycle 2 | 37.0 | SF-12 | N/A | Patients | No |
PCS, cycle 3 | 38.6 | |||||
MCS, cycle 2 | 47.7 | |||||
MCS, cycle 3 | 44.2 | |||||
PCS, cycle 2 | 52.9 | Caregivers | Potential to estimate SF-6D for caregivers to mNSCLC patients, for SMC or CADTH | |||
PCS, cycle 3 | 53.4 | |||||
MCS, cycle 2 | 46.2 | |||||
MCS, cycle 3 | 44.6 | |||||
Lloyd 2005c [66] Stage IV NSCLC | RES | 0.70 | SGk | N/A | General public | No |
SDis, oral treatment | 0.63 | |||||
SDis, i.v. treatment | 0.58 | |||||
PD | 0.42 | |||||
End of life | 0.33 | |||||
Manser 2006 [61] Stage IV NSCLC | Stage IV | Median, 0.68 (IQR, 0.54–0.82) | AQoL | Australia | Mixed stage enrolled: I, 31.5%; II, 17.4%; IIIa, 16.3%; IIIb, 7.6%; IV, 25.0% | No |
Matza 2014 [67] Stage IV cancer with bone metastases | Cancer with bone metastases and no SRE | 0.47 (0.41) | TTO | N/A | General public, UK (Edinburgh and London) | No |
0.47 (0.45) | General public, Canada (Montreal and Toronto) | |||||
0.47 (0.42) | General public, UK and Canada | |||||
Stewart 2015 [56] EGFR+ Stage IV NSCLC | PR/SDis on EGFR TKIs (GEF, ERL, AZD9291) | 0.82 (SE, 0.16) | EQ-5D-3 L | NR | Patients, eligible for or on TKI tx, 55% Asian, 45% male, median age 60, 66% never smokers. Stage IV: at diagnosis, 80% when surveyed, 100% | Unclear |
Responded to standard chemotherapy | 0.80 (SE, 0.12) | |||||
EGFR+, responded to GEF | 0.84 (SE, 0.14) | |||||
EGFR+, responded to ERL | 0.82 (SE, 0.17) | |||||
EGFR+, responded to AZD9291 | 0.83 (SE, 0.16) | |||||
EGFR+, PD during TKI treatment (GEF, ERL, AZD9291) | 0.74 (SE, 0.08) | |||||
EGFR+, all patients (PR/SDis/PD), 25% 3LL | 0.802 | |||||
Tabberer 2006 [52] Advanced NSCLC | RES | 0.49 | EQ-5D | NR | General public, UK (Cardiff, Glasgow, London and Oxford) | No |
SDis | 0.46 | |||||
SDis + oral treatment | 0.45 | |||||
SDis + i.v. treatment | 0.43 | |||||
PD | 0.22 | |||||
Near death | 0.15 | |||||
Trippoli 2001 [53] Metastatic NSCLC | Metastatic NSCLC | 0.53 (0.36) | EQ-5D | UK (TTO) | Italian patients | Meets NICE and SMC reference cases |
0.55 (0.22)l | EQ-5D VAS | N/A | No | |||
Yang 2014 [54] Stage IIIB/IV NSCLC | Stage IV inoperable, performance status 0–1 | 0.75 (0.22) | EQ-5D | Taiwan | Patients, mixed NSCLC stages: I, 0.8%; II, 0%; IIIA, 4.5%; IIIB, 16.9%; IV, 77.8% | No |
Stage IV inoperable, performance status 0–4 | 0.75 (0.22) | |||||
Yokoyama 2013c [55] Advanced NSCLC/SCLC | Stage IIIB/IV NSCLC/SCLC with bone metastasis and SRE | NR | EQ-5D | NR | Patients, advanced NSCLC, 72%, SCLC, 28% NSCLC and SCLC: IIIB, 37%; IV, 63% | No |